Experimental study of USPIO-enhanced MRI in the detection of atherosclerotic plaque and the intervention of atorvastatin

Sha,Ting; Qi,Chunmei; Fu,Wei; Hao,Ji; Gong,Lei; Wu,Hao; Zhang,Qingdui

doi:10.3892/etm.2016.3266

Experimental study of USPIO-enhanced MRI in the detection of atherosclerotic plaque and the intervention of atorvastatin

Authors:
- Ting Sha
- Chunmei Qi
- Wei Fu
- Ji Hao
- Lei Gong
- Hao Wu
- Qingdui Zhang
View Affiliations

Affiliations: Institute of Cardiovascular Diseases, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, The Second Affiliated Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China
Published online on: April 19, 2016 https://doi.org/10.3892/etm.2016.3266
Pages: 141-146
Copyright: © Sha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ultrasmall superparamagnetic iron oxide (USPIO) can identify atherosclerotic vulnerable plaque and atorvastatin can stabilize vulnerable plaque by inhibiting the inflammatory response. Using balloon injury in rabbit abdominal aortic endothelial cells and p53 gene transfecting the local plaque, we established an atherosclerotic vulnerable plaque model. In the treatment group, animals were treated with atorvastatin for 8 weeks. At the end of week 16, the animals in each group underwent medication trigger. USPIO-enhanced MRI was utilized to detect vulnerable plaque formation and the transformation of stable plaque in the treatment group. Pathological and serological studies were conducted in animal sera and tissues. The images from the USPIO‑enhanced MRI, and the vulnerable plaque showed low signal, especially on T2*-weighted sequences (T2*WI). Plaque signal strength reached a negative enhancement peak at 96 h. Compared with the other groups, lipids, cell adhesion molecule-1 and vascular cell adhesion molecule-1 levels were significantly lower (P<0.05) in the treatment group. In conclusion, USPIO‑enhanced MRI can identify vulnerable plaque formation by deposition in macrophages, while atorvastatin is able to inhibit the progression of atherosclerosis and promote plaque transformation to the stable form.

View Figures

View References

1	Virani SS, Polsani VR and Nambi V: Novel markers of infam-mation in atherosclerosis. Curr Atheroscler Rep. 10:164–170. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kleemann R, Zadelaar S and Kooistra T: Cytokines and athero-sclerosis: A comprehensive review of studies in mice. Cardiovasc Res. 79:360–376. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wang HD, Yu SQ, Gao F and Qin ML: The anti-atherosclerosiseffect of adiponectin. Chongqing Med J. 38:2509–2510. 2009.(In Chinese).
4	Pasceri V, Willerson JT and Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2165–2168. 2002. View Article : Google Scholar
5	Beck B, Weintraub W and Alexander R: Elevation of C-reactive protein in ‘active’ coronary artery disease. AMJ Cardiol. 65:168–172. 1990. View Article : Google Scholar
6	Ross R: Atherosclerosis - an infammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
7	Tang T, Howarth SP, Miller SR, Trivedi R, Graves MJ, King-Im JU, Li ZY, Brown AP, Kirkpatrick PJ, Gaunt ME, et al: Assessment of infammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 37:2266–2270. 2006. View Article : Google Scholar : PubMed/NCBI
8	Howarth SP, Tang TY, Graves MJ, U-King-Im JM, Li ZY, Walsh SR, Gaunt ME and Gillard JH: Non-invasive MR imaging of infammation in a patient with both asymptomatic carotidatheroma and an abdominal aortic aneurysm: A case report. Ann Surg Innov Res. 1:42007. View Article : Google Scholar : PubMed/NCBI
9	Metz S, Beer AJ, Settles M, Pelisek J, Botnar RM, Rummeny EJ and Heider P: Characterization of carotid artery plaques with USPIO-enhanced MRI: Assessment of infammation and vascu-larity as in vivo imaging biomarkers for plaque vulnerability. Int J Cardiovasc Imaging. 27:901–912. 2011. View Article : Google Scholar : PubMed/NCBI
10	Truskey GA, Herrmann RA, Kait J and Barber KM: Focalincreases in vascular cell adhesion molecule-1 and intimal macrophages at atherosclerosis-susceptible sites in the rabbit aorta after short-term cholesterol feeding. Arterioscler Thromb Vasc Biol. 19:393–401. 1999. View Article : Google Scholar : PubMed/NCBI
11	Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW and Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 107:1255–1262. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, et al: Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 349:2316–2325. 2003. View Article : Google Scholar : PubMed/NCBI
13	Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB and Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 350:1387–1397. 2004. View Article : Google Scholar : PubMed/NCBI
14	Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K and Tracy RP: C-reation protein and the future risk of thromboembolic stroke in healthy men. Circulation. 107:2016–2020. 2003. View Article : Google Scholar : PubMed/NCBI
15	Schupp M, Janke J, Clasen R, Unger T and Kintscher U: Angiotensin type-1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 109:2054–2057. 2004. View Article : Google Scholar : PubMed/NCBI
16	Padda RS, Shi Y, Lo CS, Zhang SL and Chan JS: Angiotensin-(1–7): A novel peptide to treat hypertension and nephropathy in diabetes? J Diabetes Metab. 6:1–6. 2015.
17	Padda RS, Gkouvatsos K, Guido M, Mui J, Vali H and Pantopoulos K: A high-fat diet modulates iron metabolism but does not promote liver fibrosis in hemochromatotic Hjv^−/− mice. Am J Physiol Gastrointest Liver Physiol. 308:G251–G261. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kurz KD, Main BW and Sandusky GE: Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 60:269–280. 1990. View Article : Google Scholar : PubMed/NCBI
19	Chen WQ, Zhang Y, Zhang M, Ji XP, Yin Y and Zhu YF: Establishing an animal model of unstable atherosclerotic plaques. Chin Med J (Engl). 117:1293–1298. 2004.PubMed/NCBI
20	Chen WQ, Zhang L, Liu YF, Chen L, Ji XP, Zhang M, Zhao YX, Yao GH, Zhang C, Wang XL, et al: Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol. 293:H2836–H2844. 2007. View Article : Google Scholar : PubMed/NCBI
21	Cormode DP, Skajaa T, Fayad ZA and Mulder WJ: Nanotechnology in medical imaging: Probe design and applications. Arterioscler Thromb Vasc Biol. 29:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JG, Barazza A, Ma Y, Fisher EA and Fayad ZA: An ApoA-Imimetic peptide high-density-lipoprotein-based MRI contrastagent for atherosclerotic plaque composition detection. Small. 4:1437–1444. 2008. View Article : Google Scholar : PubMed/NCBI
23	Clarke SE, Beletsky V, Hammond RR, Hegele RA and Rutt BK: Validation of automatically classified magnetic resonance images for carotid plaque compositional analysis. Stroke. 37:93–97. 2006. View Article : Google Scholar : PubMed/NCBI
24	Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D and Stefanadis C: Vulnerable plaque and inflammation: Potential clinical strategies. Curr Pharm Des. 17:4190–4209. 2011. View Article : Google Scholar : PubMed/NCBI
25	Li D, Chen H, Romeo F, Sawamura T, Saldeen T and Mehta JL: Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: Role of LOX-1. J Pharmacol Exp Ther. 302:601–605. 2002. View Article : Google Scholar : PubMed/NCBI
26	Li DY, Chen HJ and Mehta JL: Statins inhibit oxidized-LDL-medated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res. 52:130–135. 2001. View Article : Google Scholar : PubMed/NCBI